Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corrective Actions "Inadequate," U.S. FDA Warns Ranbaxy; Threatens Seizure And Injunction

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Ranbaxy's four-year-long tangle with U.S. FDA over the Indian firm's troubled manufacturing sites took one more serious turn as the world's most powerful regulatory agency fired another salvo saying: "It is apparent that Ranbaxy's attempts to make global corrections after past regulatory actions by the FDA have been inadequate.
Advertisement

Related Content

Ranbaxy Shutters Liquids Unit At Gloversville Citing Rationalization; Keeps Optimism On Lipitor Exclusivity
Ranbaxy Shutters Liquids Unit At Gloversville Citing Rationalization; Keeps Optimism On Lipitor Exclusivity
Ranbaxy Shutters New York Liquids Unit Citing Rationalization, Keeps Optimism On Lipitor Exclusivity
Ranbaxy Shutters New York Liquids Unit Citing Rationalization, Keeps Optimism On Lipitor Exclusivity
Ranbaxy May Be Hit With Significant Disgorgement Penalty For GMP Violations
Ranbaxy Shuffles Its CEO Again, Atul Sobti Steps Down As Daiichi Sankyo Appoints New Leader
CEO Shuffle: Daiichi Sankyo Appoints Second New Ranbaxy Leader In Less Than 15 Months
Ranbaxy Outperforms Behind Generic Valtrex, But FDA Corrective Action Looms
Ranbaxy Woes Continue With 30-plus Product Import Alert
Ranbaxy Woes Continue With 30-plus Product Import Alert
Advertisement
UsernamePublicRestriction

Register

SC074181

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel